Quanterix CEO Everett Cunningham Steps Down

Jim Gute, the company's chief commercial officer, becomes interim president and CEO while the board searches for a permanent leader.

Updated on Nov. 18, 2026 in Alzheimer’s

Quanterix CEO Everett Cunningham Steps Down

Quanterix CEO Everett Cunningham departed the company after 10 months in the role, which he began January 19. The company said he left after accepting another opportunity.

Why it matters

The abrupt leadership change comes at a time when Quanterix is seeking to grow its core business, and analysts at Leerink said transformation and a return to growth will take time to realize. The company's blood-based testing tools are part of a field that gained momentum after FDA clearance of a blood test for Alzheimer's disease.

The company's board engaged a nationally recognized executive search firm, and Quanterix's Simoa assay clinical data was published in the journal Nature. The permanent CEO search is ongoing, and the source does not say when a successor will be chosen.

The players

Quanterix

Quanterix is a life sciences company that develops ultra-sensitive assays for detecting disease biomarkers, including tests for neurological conditions such as Alzheimer's disease.

Everett Cunningham

Everett Cunningham previously served as chief commercial officer at Illumina, a genomics company, before leading Quanterix.

Jim Gute

Jim Gute joined Quanterix as chief commercial officer in August and now serves as interim president and CEO.

The details

Quanterix's board engaged a nationally recognized executive search firm to find a permanent leader and is considering both internal and external candidates. Jim Gute, hired as chief commercial officer in August, assumed the interim role.

Timeline

  1. May 2025: FDA cleared Fujirebio's Lumipulse Alzheimer's blood test.

  2. August: Jim Gute was hired as Quanterix chief commercial officer.

  3. January 19: Everett Cunningham became Quanterix president and CEO.

  4. November 18: Cunningham's departure and Gute's interim appointment were announced.

Market Landscape

The FDA's May 2025 clearance of Fujirebio's Lumipulse Alzheimer's blood test has made blood-based diagnostics a competitive commercial field. Quanterix's leadership change comes as it works to compete in that emerging market.

Blood-based Alzheimer's tests could make earlier screening more accessible to patients than costlier imaging or spinal fluid tests. Leadership changes at diagnostic companies may affect the pace at which those tests reach clinics.

The takeaway

Investors and patients should watch whether Quanterix names a permanent leader with a clear plan for its core business, since that will shape how quickly blood-based Alzheimer's testing tools reach clinical use.

Further reading

Explore more Alzheimer's coverage for context on the diagnostic tools driving this market.

Source note: This article includes information reported by FierceBiotech - free daily biotech briefing.